The clinicopathologic significance of the loss of BAF250a (ARID1A) expression in endometrial carcinoma

International Journal of Gynecological Cancer

Volumn 24, Issue 3, 2014, Pages 534-540

  Zhang, Zheng Mao ^a   Xiao, Shuang ^a   Sun, Guang Yu ^a   Liu, Yue Ping ^a   Zhang, Feng Hua ^a   Yang, Hong Fang ^a   Li, Jia ^a   Qiu, Hong Bing ^a   Liu, Yang ^a   Zhang, Chao ^b   Kang, Shan ^a   Shan, Bao En ^b  

^a HEBEI GENERAL HOSPITAL   (China)

^b HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

ARID1A; BAF250a; Endometrial carcinoma; Estrogen receptor; P53

Indexed keywords

AT RICH INTERACTIVE DOMAIN 1A PROTEIN; BIOLOGICAL MARKER; ESTROGEN RECEPTOR; GLUCOCORTICOID RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ARID1A PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTION FACTOR; TUMOR MARKER;

ARTICLE; CANCER GRADING; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CLEAR CELL CARCINOMA; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DOWN REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR DIFFERENTIATION; TUMOR INVASION; CARCINOMA; ENDOMETRIUM; ENDOMETRIUM TUMOR; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

CARCINOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; HUMANS; MIDDLE AGED; NUCLEAR PROTEINS; PROGNOSIS; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84900416405     PISSN: 1048891X     EISSN: 15251438     Source Type: Journal    
DOI: 10.1097/IGC.0000000000000092     Document Type: Article

References (23)

1. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67-73.
2. Bosse T, ter Haar NT, Seeber LM, et al. Loss of ARID1A expression and its relationship with PI3K-Akt pathway alterations, TP53 and microsatellite instability in endometrial cancer. Mod Pathol. 2013;26:1525-1535.
3. Rahman M, Nakayama K, Rahman MT, et al. Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. Hum Pathol. 2013;44:103-109.
4. Huang J, Zhao YL, Li Y, et al. Genomic and functional evidence for an ARID1A tumor suppressor role. Genes Chromosomes Cancer. 2007;46:745-750.
5. Lowery WJ, Schildkraut JM, Akushevich L, et al. Loss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancers. Int J Gynecol Cancer. 2012;22:9-14.
6. Guan B, Mao TL, Panuganti PK, et al. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma. Am J Surg Pathol. 2011;35:625-632.
7. Werner HM, Berg A, Wik E, et al. ARID1A loss is prevalent in endometrial hyperplasia with atypia and low-grade endometrioid carcinomas. Mod Pathol. 2013;26:428-434.
8. McConechy MK, Ding J, Cheang MC, et al. Use of mutation profiles to refine the classification of endometrial carcinomas. J Pathol. 2012;228:20-30.
9. Wang X, Nagl NG Jr, Flowers S, et al. Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors. Int J Cancer. 2004;112:636.
10. Wang X, Nagl NG, Wilsker D, et al. Two related ARID family proteins are alternative subunits of human SWI/SNF complexes. Biochem J. 2004;383:319-325.
11. van Rechem C, Boulay G, Leprince D. HIC1 interacts with a specific subunit of SWI/SNF complexes, ARID1A/BAF250A. Biochem Biophys Res Commun. 2009;385:586-590.
12. Kohler MF, Berchuck A, Davidoff AM, et al. Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res. 1992;52:1662.
13. Guan B, Wang TL, Shih IeM. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. Cancer Res. 2011;71:6718-6727.
14. Garg K, Leitao MM Jr, Wynveen CA, et al. p53 overexpression in morphologically ambiguous endometrial carcinomas correlates with adverse clinical outcomes. Mod Pathol. 2010;23:80-92.
15. Fadare O, Gwin K, Desouki MM, et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium. Mod Pathol. 2013;26:1101-1110.
16. Liu G, Schwartz JA, Brooks SC. p53 down-regulates ER-responsive genes by interfering with the binding of ER to ERE. Biochem Biophys Res Commun. 1999;264:359-364.
17. Inoue H, Giannakopoulos S, Parkhurst CN, et al. Target genes of the largest human SWI/SNF complex subunit control cell growth. Biochem J. 2011;434:83-92.
18. Jazaeri O, Shupnik MA, Jazaeri AA, et al. Expression of estrogen receptor alpha mRNA and protein variants in human endometrial carcinoma. Gynecol Oncol. 1999;74:38-47.
19. Trotter KW, Archer TK. Reconstitution of glucocorticoid receptor-dependent transcription in vivo. Mol Cell Biol. 2004;24:3347-3358.
20. Maeda D, Mao TL, Fukayama M, et al. Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma. Int J Mol Sci. 2010;11:5120-5128.
21. Katagiri A, Nakayama K, Rahman MT, et al. Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. Mod Pathol. 2012;25:282-288.
22. Gao X, Tate P, Hu P, et al. ES cell pluripotency and germ-layer formation require the SWI/SNF chromatin remodeling component BAF250a. Proc Natl Acad Sci U S A. 2008;105:6656-6661.
23. Ayhan A, Mao TL, Seckin T, et al. Loss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinoma. Int J Gynecol Cancer. 2012;22:1310-1315.